title: Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertension.
abstract: Osteopontin (OPN) has recently emerged as a key factor in both vascular remodelling and development of atherosclerosis. It has been reported that OPN is regulated by the renin-angiotensin-aldosterone system (RAAS). The aim of this study was to clarify the effect of angiotensin II receptor blockade with valsartan on plasma OPN levels in patients with essential hypertension (EHT). Forty-six patients (mean age, 64±11 years) with EHT were randomly assigned to treatment with amlodipine or valsartan. There were no significant differences in baseline clinical characteristics between the two groups. Blood sampling and blood pressure evaluation were performed before and after 24 weeks of treatment. After 24 weeks, both systolic blood pressure (SBP) and diastolic blood pressure (DBP) were decreased significantly and by the same degree in each treatment group. However, valsartan but not amlodipine decreased plasma OPN levels (baseline and 24-week data-valsartan: 614±224 ng ml(-1), 472±268 ng ml(-1), P=0.006; amlodipine: 680±151 ng ml(-1), 687±234 ng ml(-1), P>0.999). A positive correlation between the reduction in OPN and the log natural (ln) C-reactive protein (CRP) was seen in the valsartan-treated group. Stepwise regression analysis showed that treatment with valsartan and the reduction of ln CRP were associated with the reduction in OPN levels, and this association was independent of the reduction in SBP or aldosterone levels (valsartan: β=0.332, P=0.026; ln CRP reduction: β=0.366, P=0.015). These results suggest that suppression of the RAAS and inflammation may decrease plasma OPN levels.
authors.affiliation: Department of Integrated Medicine and Informatics, Ehime University Graduate School of Medicine, Shitsukawa, Toon City, Ehime, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Kurata
authors.forename: T
authors.initials: T
authors.lastname: Okura
authors.forename: J
authors.initials: J
authors.lastname: Irita
authors.forename: D
authors.initials: D
authors.lastname: Enomoto
authors.forename: T
authors.initials: T
authors.lastname: Nagao
authors.forename: M
authors.initials: M
authors.lastname: Jotoku
authors.forename: K
authors.initials: K
authors.lastname: Miyoshi
authors.forename: V R
authors.initials: VR
authors.lastname: Desilva
authors.forename: J
authors.initials: J
authors.lastname: Higaki
mesh_terms: D000368:Aged; D017311:Amlodipine / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000032:analysis; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D053495:Osteopontin / Q000097:blood*; D013777:Tetrazoles / Q000627:therapeutic use*; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068756:Valsartan
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D013777:Tetrazoles; D053495:Osteopontin; D017311:Amlodipine; D000068756:Valsartan; D002097:C-Reactive Protein; D014633:Valine